Loading clinical trials...
Loading clinical trials...
A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Co-Administered With Acetaminophen for the Treatment of Acute Migraine.
The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are called rizatriptan given with acetaminophen.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
SanFrancisco Headache Clinic
San Francisco, California, United States
Diamond Headache Clinic
Chicago, Illinois, United States
Westside Family Medical Center
Kalamazoo, Michigan, United States
Clinvest
Springfield, Missouri, United States
Mercy Health Research
St Louis, Missouri, United States
Elkind Headache Center
Mount Vernon, New York, United States
ClinExcel
West Chester, Ohio, United States
Start Date
March 1, 2006
Primary Completion Date
January 1, 2007
Completion Date
January 1, 2007
Last Updated
May 28, 2008
200
Estimated participants
Rizatriptan co-administered with Acetaminophen
DRUG
Lead Sponsor
Diamond Headache Clinic
Collaborators
NCT06641466
NCT07018713
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions